300 results on '"Jurinovic, Vindi"'
Search Results
2. Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group
3. Differentiation of benign and metastatic lymph nodes in soft tissue sarcoma
4. TGFβ signalling pathway impacts brain metastases profiles in locally advanced colorectal cancer
5. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
6. Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms
7. Large-scale benchmark study of survival prediction methods using multi-omics data
8. In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance
9. Adverse stem cell clones within a single patient’s tumor predict clinical outcome in AML patients
10. Stage‐adapted treatment of HIV‐associated Hodgkin lymphoma: Long‐term results of a prospective, multicenter study.
11. The association of immunosurveillance and distant metastases in colorectal cancer
12. A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
13. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study
14. Improved outcomes in metastatic germ cell cancer: results from a large cohort study
15. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19
16. Sex-associated differences in frequencies and prognostic impact of recurrent genetic alterations in adult acute myeloid leukemia (Alliance, AMLCG)
17. Development and validation of multivariate predictors of primary endocrine resistance to tamoxifen and aromatase inhibitors in luminal breast cancer reveal drug-specific differences
18. Differentiation of benign and metastatic lymph nodes in soft tissue sarcoma
19. Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia
20. In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
21. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
22. Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo
23. Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma: A Follow-Up Study of 2 Randomized Trials from the German Low Grade Lymphoma Study Group
24. FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy
25. Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms
26. Supplementary Figures from Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients
27. Table S4 from Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients
28. WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice
29. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
30. Additional file 2 of Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo
31. Additional file 1 of Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo
32. Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia
33. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
34. X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL
35. Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection
36. Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])
37. Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML
38. Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML
39. Indirect Comparison of Interaction Graphs
40. Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
41. Additional file 4 of Adverse stem cell clones within a single patient���s tumor predict clinical outcome in AML patients
42. Additional file 3 of Adverse stem cell clones within a single patient���s tumor predict clinical outcome in AML patients
43. Additional file 1 of Adverse stem cell clones within a single patient���s tumor predict clinical outcome in AML patients
44. Additional file 5 of Adverse stem cell clones within a single patient���s tumor predict clinical outcome in AML patients
45. Additional file 2 of Adverse stem cell clones within a single patient���s tumor predict clinical outcome in AML patients
46. Additional file 7 of Adverse stem cell clones within a single patient���s tumor predict clinical outcome in AML patients
47. Additional file 8 of Adverse stem cell clones within a single patient���s tumor predict clinical outcome in AML patients
48. Additional file 6 of Adverse stem cell clones within a single patient���s tumor predict clinical outcome in AML patients
49. X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL.
50. CHOP but Not Bendamustine Reverses EZH2 Y641 Mutation Induced MHC-I/II Loss in Human Lymphoma Models
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.